Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 14/20 | 0.72 |
| ▸ | AKR1C2 | P52895 | 14/20 | 0.72 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27782035 | 0.89 | AKR1C3 (0.58) | AKR1C3AKR1C2PSEN1PSEN2APH1B | |
| SCHEMBL29009950 | 0.87 | AKR1C3 (0.64) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL30428628 | 0.85 | AKR1C3 (0.64) | AKR1C3AKR1C2PSEN1PSEN2APH1B | |
| SCHEMBL23070581 | 0.84 | AKR1C3 (1.00) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1781777 | 0.83 | AKR1C3 (0.53) | AKR1C3AKR1C2AKR1C4AKR1C1PTGS1 | |
| SCHEMBL1567845 | 0.82 | AKR1C3 (0.63) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL11270744 | 0.81 | AKR1C3 (0.59) | AKR1C3AKR1C2PSEN1PSEN2APH1B | |
| SCHEMBL29009770 | 0.81 | AKR1C3 (0.59) | AKR1C3AKR1C2PSEN1PSEN2APH1B | |
| SCHEMBL24281943 | 0.80 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C4AKR1C1KDR | |
| SCHEMBL5123820 | 0.80 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C4AKR1C1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-12-27 | — | — | US | disclosed |
| CN-104955454-B | Chemokine receptor anagonists | 凯莫森特里克斯股份有限公司 | 2018-06-29 | — | — | CN | disclosed |
| EP-2888261-B1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| EP-1933622-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1933622-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| WO-2007109154-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109192-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | AKR1C3 717/4885AKR1C2 1470/4885APP 4354/4885 |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | AKR1C3 3322/4885AKR1C2 2975/4885APP 99/4885 |
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | AKR1C3 717/4885AKR1C2 1470/4885APP 4354/4885 |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | AKR1C3 1419/4885AKR1C2 2324/4885APP 1068/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | AKR1C3 1193/4885AKR1C2 1007/4885APP 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.